查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1532132

醫藥市場：依分子類型、依產品、依類型、依給藥途徑、依劑型、依年齡組、依疾病類型、依地區、機會、預測，2017-2031

Pharmaceutical Market Assessment, By Molecule Type, By Product, By Type, By Route of Administration, By Dosage Form, By Age-Group, By Disease Type, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 243 Pages | 商品交期: 3-5個工作天內

價格

2024-2031年預測期間，全球醫藥市場規模將以年複合成長率6.52%擴大，從2023年的16,070億美元成長到2031年的2,663,580百萬美元。由於疾病負擔增加、老年人口增加以及政府為提高人們獲得藥品的機會而採取的舉措的影響，預計該市場在預測期內將以更高的速度成長。

藥品在醫療保健領域發揮著極其重要的作用，對整個護理流程產生重大影響。隨著醫療保健和製藥行業的不斷進步，疾病負擔的增加和隨之而來的藥品需求的膨脹是市場的主要驅動力。監管部門的批准和專利狀況決定了特定藥物的市場狀況。由於人口變化、技術進步以及全球對醫療保健解決方案的需求不斷成長，預計製藥市場將繼續成長。隨著新興市場地位的增強，全球醫藥市場的動態預計將發生變化，為產業參與者帶來挑戰和機會。例如，美國食品藥物管理局（USFDA）在2021年至2023年期間批准了142個新藥，其中2021年有50個藥物，2022年有37個藥物，2023年有55個藥物已獲得批准並上市。

本報告調查了全球藥品市場並提供了市場概況，包括依產品、類型、給藥途徑、劑型、年齡組、疾病類型、地區和市場進入的趨勢。

目錄

第1章 專案範圍與定義

第2章 研究方法

第3章 執行摘要

第4章 2017-2031年全球醫藥市場展望

  • 市場規模分析與預測
  • 市佔率分析與預測
  • 2023年市場地圖分析
    • 依分子型
    • 依產品
    • 依類型
    • 依給藥途徑
    • 依劑型
    • 依年齡段
    • 依疾病類型
    • 依地區

第5章 北美醫藥市場展望，2017-2031

第6章 歐洲醫藥市場展望，2017-2031

第7章 亞太地區醫藥市場展望，2017-2031

第8章 南美洲製藥市場展望，2017-2031

第9章 中東與非洲醫藥市場展望，2017-2031

第10章 供需分析

第11章 進出口分析

第12章 價值鏈分析

第13章 波特五力分析

第14章 PESTLE分析

第15章 價格分析

第16章 市場動態

  • 市場驅動因素
  • 市場挑戰

第17章 市場趨勢與發展

第18章 監理架構與創新

第19章 專利狀況

第20章 個案研究

第21章 競爭態勢

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名參與公司的 SWOT 分析
  • 市場前10位主要參與者的情況
    • Pfizer Inc.
    • AbbVie Inc.
    • Johnson & Johnson Services, Inc.
    • Merck & Co.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Sanofi S.A.
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
    • GSK plc

第22章 策略建議

第23章 查詢及免責聲明

Product Code: MX11747

Global pharmaceutical market is projected to witness a CAGR of 6.52% during the forecast period 2024-2031, growing from USD 1607 billion in 2023 to USD 2663.58 billion in 2031. Under the influence of inflating disease burden, growing geriatric population, and government efforts to enhance pharmaceutical access for people, the market is anticipated to thrive further at a higher momentum during the forecast period.

Pharmaceutical products play a pivotal role in the healthcare sector and drive a major impact on the entire process of caregiving. With growing advancements in healthcare and pharma industry, rising disease burden and subsequent inflation in demand for pharmaceutical products are some of the major driving forces of the market. Regulatory approvals and patent landscape determine the market status of a particular drug. The pharmaceutical market is up for continued growth, driven by demographic changes, technological advancements, and the increasing global demand for healthcare solutions. As emerging markets strengthen their positions, the dynamics of the global pharmaceutical landscape will evolve, presenting both challenges and opportunities for industry stakeholders. The new drug launches keep this market active, for instance, the United States Food and Drug Association (USFDA) approved 142 novel drugs between 2021-2023, out of which 50 drugs were approved and launched in 2021, 37 drugs in 2022, and 55 drugs in 2023.

Rising Burden of Global Disease to Increase the Global Pharmaceutical Market Size

The global disease burden has been on rise from last few decades and is anticipated to keep rising in future due to changes in lifestyle and growing global population. The demand is mainly driven by the need for effective treatments, pharmaceutical innovation, and global health initiatives aimed at addressing health disparities across countries. The strategic use of global disease burden case can be useful for pipeline investment tool and take advantage of market opportunity in the forecast period. The National Institute of Health (NIH) projects a 99.5% (95.1%-107.9%) increase in the number of adults 50 years of age and older with at least one chronic illness by 2050, from 71.522 million (69.065-73.781) in 2020 to 142.66 million (134.74-153.39). An estimated 48 million people (or 47% of deaths globally) are expected to die from severe health-related suffering by 2060, an 87% increase from 26 million in 2016. It is anticipated that 83% of these deaths will occur in low and middle-income countries.

Government Support to Boost Pharmaceutical Market

Governments across the globe are actively boosting their pharmaceutical sectors through various initiatives such as increased investments in research and development (R&D), improving regulatory frameworks to ease the conduct of businesses, and implementing production-linked incentive schemes to boost the manufacturing and supply chains. Initiatives in major pharmaceutical producing countries like India's focus on improving healthcare access and affordability is expected to add to the market growth. India's National Policy on Research and Development aim to foster collaboration between industry and academia, and programs such as Ayushman Bharat and Pradhan Mantri Bhartiya Janaushadhi Pariyojana promote the pharmaceutical market. Similarly, the United States government, is working on multiple fronts through USFDA, NIH, and other organizations to enhance the pharmaceutical availability, while European governments working on subsidies, fundings, and enhancing supply chain.

Dominance of Branded Drugs in the Pharmaceutical Market

The branded drugs segment is anticipated to contribute with larger market share in pharmaceutical market due to inflated cost and high demand. Branded drugs are highly specialized and are covered by patents to be exclusive to only a single manufacturer, which significantly inflates the market price for branded drugs. The branded drugs become generic and open to other market players for production and marketing after the expiry of patents on it, and generic drugs are comparatively much cheaper due to competition in the market. The newly launched drugs add more share to this segment and robust pipeline of innovative drugs from various market players is anticipated further to increase the market share of branded drug segment. For instance, USFDA approved 23 drugs till July 2024 and around 430 clinical trials are in third phase which are expected to be completed in 2024, resulting into launch of more drugs.

North America Dominates Pharmaceutical Market Share

North America is anticipated to demonstrate dominance in the global pharmaceutical market, owing to enhanced access to high-value medications, extensive awareness about healthcare, high per-capita healthcare expenditure, and firm gross domestic product (GDP) condition of North American countries like the United States and Canada. High reliance on prescription drugs, and strict regulatory policy impact the market in the region. Strategic partnerships among market players in the region contribute to the dominance of the region. For instance, in 2024, Isomorphic Labs announced strategic collaborations with two major pharmaceutical companies, Eli Lilly and Novartis, which could be valued at nearly USD 3 billion, excluding potential royalties from future drug sales. These partnerships are focused on multi-target drug development involving small molecules and feature a combination of upfront and milestone payments, highlighting Isomorphic's innovative approach to drug design and its progress in the pharmaceutical industry.

Future Market Scenario (2024 - 2031F)

Government and regulatory attempts across the countries to reduce the cost of drugs is anticipated to bring a major disruption in the market. These attempts include reducing drug companies' exclusivity window, policy reforms to control drug costs, and forming stricter regulatory policies.

Demographic shift in various countries such as Japan, Spain, Switzerland, and others is anticipated to impact the demand of specific type of drugs in the forecast period. Meanwhile, economic imbalance is expected to further define the future market scenario.

Key Players Landscape and Outlook

The pharmaceutical market is quite competitive with a huge number of players at local levels. Regulatory approvals of company products, mergers and acquisitions, and collaborations are the most common market strategies which have been observed in recent times. In July 2024, Mankind Pharma acquired Bharat Serums and Vaccines Limited (BSV) in a deal worth USD 1.64 billion. The acquisition will expand the domestic pharma business and its specialty pharma portfolio. BSV is the major vaccine developer in India and has R&D facilities in other countries such as Ukraine, Germany, Malaysia, and Philippines. The acquisition will place Mankind Pharma as a market leader in women's health and fertility segment in India.

In December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc. The deal was initiated in March 2023 and was completed in December 2023. Seagen Inc. is a global biotechnology company that is involved in the discovery, development, and commercialization of transformative cancer medicines. Pfizer completed the acquisition of its outstanding common stock of Seagen for USD 229 in cash per share, for a total enterprise value of approximately USD 43 billion. Through this acquisition Pfizer's Oncology pipeline will be doubled in size with 60 programs spanning multiple domains, including ADCs, small molecules, bispecific, and other immunotherapies.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Pharmaceutical Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Molecule Type
      • 4.2.1.1. Small Molecules (Conventional Drugs)
      • 4.2.1.2. Large Molecules
        • 4.2.1.2.1. Biologics
        • 4.2.1.2.2. Biosimilars
    • 4.2.2. By Product
      • 4.2.2.1. Branded
      • 4.2.2.2. Generic
    • 4.2.3. By Type
      • 4.2.3.1. Prescription-based
      • 4.2.3.2. Over-the-Counter Drugs
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Topical
      • 4.2.4.3. Parenteral
        • 4.2.4.3.1. Intravenous
        • 4.2.4.3.2. Intramuscular
        • 4.2.4.3.3. Others
      • 4.2.4.4. Inhalational
      • 4.2.4.5. Others
    • 4.2.5. By Dosage Form
      • 4.2.5.1. Tablets
      • 4.2.5.2. Capsules
      • 4.2.5.3. Injectables
      • 4.2.5.4. Powders
      • 4.2.5.5. Suspensions
      • 4.2.5.6. Syrups
      • 4.2.5.7. Sprays
      • 4.2.5.8. Others
    • 4.2.6. By Age-Group
      • 4.2.6.1. Geriatric
      • 4.2.6.2. Adults
      • 4.2.6.3. Adolescents
      • 4.2.6.4. Children
    • 4.2.7. By Disease Type
      • 4.2.7.1. Cardiovascular Diseases
      • 4.2.7.2. Oncology
      • 4.2.7.3. Diabetes
      • 4.2.7.4. Respiratory Disorders
      • 4.2.7.5. Neurology
      • 4.2.7.6. Infectious Diseases
      • 4.2.7.7. Gastrointestinal Disorders
      • 4.2.7.8. Others
    • 4.2.8. By Region
      • 4.2.8.1. North America
      • 4.2.8.2. Europe
      • 4.2.8.3. Asia-Pacific
      • 4.2.8.4. South America
      • 4.2.8.5. Middle East and Africa
    • 4.2.9. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Molecule Type
    • 4.3.2. By Product
    • 4.3.3. By Type
    • 4.3.4. By Route of Administration
    • 4.3.5. By Dosage Form
    • 4.3.6. By Age-Group
    • 4.3.7. By Disease Type
    • 4.3.8. By Region

5. North America Pharmaceutical Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Molecule Type
      • 5.2.1.1. Small Molecules (Conventional Drugs)
      • 5.2.1.2. Large Molecules
        • 5.2.1.2.1. Biologics
        • 5.2.1.2.2. Biosimilars
    • 5.2.2. By Product
      • 5.2.2.1. Branded
      • 5.2.2.2. Generic
    • 5.2.3. By Type
      • 5.2.3.1. Prescription-based
      • 5.2.3.2. Over-the-Counter Drugs
    • 5.2.4. By Route of Administration
      • 5.2.4.1. Oral
      • 5.2.4.2. Topical
      • 5.2.4.3. Parenteral
        • 5.2.4.3.1. Intravenous
        • 5.2.4.3.2. Intramuscular
        • 5.2.4.3.3. Others
      • 5.2.4.4. Inhalational
      • 5.2.4.5. Others
    • 5.2.5. By Dosage Form
      • 5.2.5.1. Tablets
      • 5.2.5.2. Capsules
      • 5.2.5.3. Injectables
      • 5.2.5.4. Powders
      • 5.2.5.5. Suspensions
      • 5.2.5.6. Syrups
      • 5.2.5.7. Sprays
      • 5.2.5.8. Others
    • 5.2.6. By Age-Group
      • 5.2.6.1. Geriatric
      • 5.2.6.2. Adults
      • 5.2.6.3. Adolescents
      • 5.2.6.4. Children
    • 5.2.7. By Disease Type
      • 5.2.7.1. Cardiovascular Diseases
      • 5.2.7.2. Oncology
      • 5.2.7.3. Diabetes
      • 5.2.7.4. Respiratory Disorders
      • 5.2.7.5. Neurology
      • 5.2.7.6. Infectious Diseases
      • 5.2.7.7. Gastrointestinal Disorders
      • 5.2.7.8. Others
    • 5.2.8. By Country Share
      • 5.2.8.1. United States
      • 5.2.8.2. Canada
      • 5.2.8.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Pharmaceutical Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Molecule Type
          • 5.3.1.2.1.1. Small Molecules (Conventional Drugs)
          • 5.3.1.2.1.2. Large Molecules
          • 5.3.1.2.1.2.1. Biologics
          • 5.3.1.2.1.2.2. Biosimilars
        • 5.3.1.2.2. By Product
          • 5.3.1.2.2.1. Branded
          • 5.3.1.2.2.2. Generic
        • 5.3.1.2.3. By Type
          • 5.3.1.2.3.1. Prescription-based
          • 5.3.1.2.3.2. Over-the-Counter Drugs
        • 5.3.1.2.4. By Route of Administration
          • 5.3.1.2.4.1. Oral
          • 5.3.1.2.4.2. Topical
          • 5.3.1.2.4.3. Parenteral
          • 5.3.1.2.4.3.1. Intravenous
          • 5.3.1.2.4.3.2. Intramuscular
          • 5.3.1.2.4.3.3. Others
          • 5.3.1.2.4.4. Inhalational
          • 5.3.1.2.4.5. Others
        • 5.3.1.2.5. By Dosage Form
          • 5.3.1.2.5.1. Tablets
          • 5.3.1.2.5.2. Capsules
          • 5.3.1.2.5.3. Injectables
          • 5.3.1.2.5.4. Powders
          • 5.3.1.2.5.5. Suspensions
          • 5.3.1.2.5.6. Syrups
          • 5.3.1.2.5.7. Sprays
          • 5.3.1.2.5.8. Others
        • 5.3.1.2.6. By Age-Group
          • 5.3.1.2.6.1. Geriatric
          • 5.3.1.2.6.2. Adults
          • 5.3.1.2.6.3. Adolescents
          • 5.3.1.2.6.4. Children
        • 5.3.1.2.7. By Disease Type
          • 5.3.1.2.7.1. Cardiovascular Diseases
          • 5.3.1.2.7.2. Oncology
          • 5.3.1.2.7.3. Diabetes
          • 5.3.1.2.7.4. Respiratory Disorders
          • 5.3.1.2.7.5. Neurology
          • 5.3.1.2.7.6. Infectious Diseases
          • 5.3.1.2.7.7. Gastrointestinal Disorders
          • 5.3.1.2.7.8. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Pharmaceutical Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Pharmaceutical Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Pharmaceutical Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Pharmaceutical Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Pfizer Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. AbbVie Inc.
    • 21.3.3. Johnson & Johnson Services, Inc.
    • 21.3.4. Merck & Co.
    • 21.3.5. Novartis AG
    • 21.3.6. F. Hoffmann-La Roche Ltd
    • 21.3.7. Sanofi S.A.
    • 21.3.8. Bristol-Myers Squibb Company
    • 21.3.9. AstraZeneca PLC
    • 21.3.10. GSK plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 3. Global Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 5. Global Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6. Global Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 7. Global Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 8. Global Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 9. Global Pharmaceutical Market Share (%), By Region, 2017-2031F
  • Figure 10. North America Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 11. North America Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 12. North America Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 13. North America Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 14. North America Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 15. North America Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 16. North America Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 17. North America Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 18. North America Pharmaceutical Market Share (%), By Country, 2017-2031F
  • Figure 19. United States Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. United States Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 21. United States Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 22. United States Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 23. United States Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 24. United States Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 25. United States Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 26. United States Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 27. Canada Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Canada Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 29. Canada Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 30. Canada Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 31. Canada Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Canada Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 33. Canada Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 34. Canada Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 35. Mexico Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 36. Mexico Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 37. Mexico Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 38. Mexico Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 39. Mexico Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 40. Mexico Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 41. Mexico Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 42. Mexico Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 43. Europe Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 44. Europe Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 45. Europe Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 46. Europe Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 47. Europe Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 48. Europe Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 49. Europe Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 50. Europe Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 51. Europe Pharmaceutical Market Share (%), By Country, 2017-2031F
  • Figure 52. Germany Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Germany Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 54. Germany Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 55. Germany Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 56. Germany Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 57. Germany Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 58. Germany Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 59. Germany Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 60. France Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. France Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 62. France Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 63. France Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 64. France Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 65. France Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 66. France Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 67. France Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 68. Italy Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 69. Italy Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 70. Italy Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 71. Italy Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 72. Italy Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73. Italy Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 74. Italy Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 75. Italy Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 76. United Kingdom Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. United Kingdom Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 78. United Kingdom Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 79. United Kingdom Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 80. United Kingdom Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 81. United Kingdom Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 82. United Kingdom Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 83. United Kingdom Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 84. Russia Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 85. Russia Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 86. Russia Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 87. Russia Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 88. Russia Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 89. Russia Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 90. Russia Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 91. Russia Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 92. Netherlands Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 93. Netherlands Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 94. Netherlands Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 95. Netherlands Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 96. Netherlands Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 97. Netherlands Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 98. Netherlands Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 99. Netherlands Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 100. Spain Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 101. Spain Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 102. Spain Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 103. Spain Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 104. Spain Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. Spain Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 106. Spain Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 107. Spain Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 108. Turkey Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 109. Turkey Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 110. Turkey Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 111. Turkey Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 112. Turkey Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 113. Turkey Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 114. Turkey Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 115. Turkey Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 116. Poland Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 117. Poland Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 118. Poland Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 119. Poland Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 120. Poland Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 121. Poland Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 122. Poland Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 123. Poland Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 124. South America Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. South America Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 126. South America Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 127. South America Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 128. South America Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 129. South America Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 130. South America Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 131. South America Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 132. South America Pharmaceutical Market Share (%), By Country, 2017-2031F
  • Figure 133. Brazil Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 134. Brazil Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 135. Brazil Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 136. Brazil Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 137. Brazil Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 138. Brazil Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 139. Brazil Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 140. Brazil Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 141. Argentina Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 142. Argentina Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 143. Argentina Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 144. Argentina Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 145. Argentina Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 146. Argentina Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 147. Argentina Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 148. Argentina Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 149. Asia-Pacific Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 150. Asia-Pacific Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 151. Asia-Pacific Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 152. Asia-Pacific Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 153. Asia-Pacific Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 154. Asia-Pacific Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 155. Asia-Pacific Pharmaceutical Market Share (%), By Age-Group, In USD Billion, 2016-2030
  • Figure 156. Asia-Pacific Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 157. Asia-Pacific Pharmaceutical Market Share (%), By Country, 2017-2031F
  • Figure 158. India Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 159. India Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 160. India Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 161. India Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 162. India Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 163. India Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 164. India Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 165. India Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 166. China Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 167. China Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 168. China Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 169. China Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 170. China Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 171. China Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 172. China Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 173. China Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 174. Japan Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. Japan Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 176. Japan Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 177. Japan Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 178. Japan Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 179. Japan Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 180. Japan Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 181. Japan Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 182. Australia Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 183. Australia Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 184. Australia Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 185. Australia Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 186. Australia Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 187. Australia Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 188. Australia Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 189. Australia Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 190. Vietnam Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 191. Vietnam Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 192. Vietnam Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 193. Vietnam Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 194. Vietnam Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 195. Vietnam Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 196. Vietnam Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 197. Vietnam Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 198. South Korea Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 199. South Korea Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 200. South Korea Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 201. South Korea Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 202. South Korea Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 203. South Korea Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 204. South Korea Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 205. South Korea Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 206. Indonesia Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 207. Indonesia Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 208. Indonesia Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 209. Indonesia Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 210. Indonesia Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 211. Indonesia Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 212. Indonesia Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 213. Indonesia Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 214. Philippines Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 215. Philippines Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 216. Philippines Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 217. Philippines Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 218. Philippines Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 219. Philippines Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 220. Philippines Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 221. Philippines Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 222. Middle East & Africa Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 223. Middle East & Africa Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 224. Middle East & Africa Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 225. Middle East & Africa Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 226. Middle East & Africa Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 227. Middle East & Africa Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 228. Middle East & Africa Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 229. Middle East & Africa Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 230. Middle East & Africa Pharmaceutical Market Share (%), By Country, 2017-2031F
  • Figure 231. Saudi Arabia Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 232. Saudi Arabia Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 233. Saudi Arabia Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 234. Saudi Arabia Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 235. Saudi Arabia Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 236. Saudi Arabia Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 237. Saudi Arabia Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 238. Saudi Arabia Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 239. UAE Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 240. UAE Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 241. UAE Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 242. UAE Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 243. UAE Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 244. UAE Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 245. UAE Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 246. UAE Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 247. South Africa Pharmaceutical Market, By Value, In USD Billion, 2017-2031F
  • Figure 248. South Africa Pharmaceutical Market Share (%), By Molecule Type, 2017-2031F
  • Figure 249. South Africa Pharmaceutical Market Share (%), By Product, 2017-2031F
  • Figure 250. South Africa Pharmaceutical Market Share (%), By Type, 2017-2031F
  • Figure 251. South Africa Pharmaceutical Market Share (%), By Route of Administration, 2017-2031F
  • Figure 252. South Africa Pharmaceutical Market Share (%), By Dosage Form, 2017-2031F
  • Figure 253. South Africa Pharmaceutical Market Share (%), By Age-Group, 2017-2031F
  • Figure 254. South Africa Pharmaceutical Market Share (%), By Disease Type, 2017-2031F
  • Figure 255. By Molecule Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 256. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 257. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 258. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 259. By Dosage Form Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 260. By Age-Group Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 261. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 262. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023